144 results about "Plasma concentration" patented technology

The invention belongs to the technical field of coating equipment, particularly relates to a chamber gas inlet pipeline and gas flow uniformizing structure of PECVD (Plasma Enhanced Chemical Vapor Deposition) equipment, and aims to solve the problems that the dispersion concentration of dissociated chamber gas of the existing PECVD equipment is non-uniform, the gas concentration close to the inlet end of a gas pipeline exceeds that of other areas, and the gas flow uniformizing structure is not uniform. In order to solve the problems that the plasma concentration is too high in the part of film forming process, the phenomenon that particulate matter is gathered on half and exceeds the standard is caused, and meanwhile the uniformity of final film forming becomes poor due to the fact that the plasma concentration is inconsistent in the film forming process, the following scheme is provided that an air inlet cavity is included. The chamber gas inlet pipeline and the gas flow uniformizing structure of the PECVD equipment disclosed by the invention can assist the gas flow uniformizing plate I and the gas flow uniformizing plate II in diffusing gas introduced from the center above the chamber to the periphery; the risk that particulate matter exceeds the standard due to uneven concentration dispersion of single-pipeline gas inlet is avoided through secondary flow uniformizing of the first gas flow uniformizing plate and the second gas flow uniformizing plate, and the added secondary flow uniformizing can further improve the uniformity of the membrane.

Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.

Described herein are methods comprising using measurements of perioperative plasma concentrations of Tau-PT217 and / or Tau-PT181 to predict which subjects are likely to develop postoperative delirium, and thereby determine which patients are most likely to benefit from intervention to reduce the risk of postoperative delirium or reduce the severity or consequence of postoperative delirium.

The invention relates to the technical field of plasma concentration monitoring methods, in particular to a method for rapidly detecting the content of tacrolimus in plasma through paper spray mass spectrometry. The method provided by the invention comprises the following steps: adding a to-be-detected plasma sample into a precipitation solution, vortex, taking supernate, and dropwise adding the supernate onto a paper base; spraying voltage is applied to the paper base, the paper base generates electrospray, and the electrospray enters a mass spectrometer for detection; preparing a gradient matrix matched tacrolimus standard solution, replacing the to-be-detected plasma sample with the gradient matrix matched tacrolimus standard solution, repeating the operation, recording a detection result, and drawing a standard curve by taking the matrix matched tacrolimus concentration as an abscissa and taking peak area data acquired by a mass spectrometer as an ordinate; and comparing the recorded detection result with the drawn standard curve, and quantitatively analyzing the content of tacrolimus in the to-be-detected plasma sample. The method disclosed by the invention is simple to operate and high in analysis speed, has relatively good precision and accuracy and also has high sensitivity and high selectivity.

To provide a method and device for predicting plasma concentration transition in combination of multiple drugs, by easily determining Ki, fm in vivo, and making them into a database, since, there has been dynamic prediction using a physiologic medicine speed theory (PBPK) model, as a prediction method of a drug interaction for medical products, however, prediction using an inhibition constant (Ki) of in vitro data and a contribution ratio (fm) of a metabolic enzyme, do not always match increase of clinical AUC.SOLUTION: There is provided a method for determining a parameter of a compartment model from a pharmacokinetic parameter of an interacted drug and interaction drug, then converting the compartment parameter into a PBPK model parameter, then determining by simulation using the PBPK model, a Ki value and fm being AUC increase ratios observed clinically. The acquired parameter is made into a database, and simulation of blood concentration transition of the interacted drug and interaction drug is performed.SELECTED DRAWING: Figure 1

The invention provides a method for detecting the blood concentration of elacycline in serum. The method comprises the following steps: pretreating a human serum sample; then detecting by adopting liquid chromatography-mass spectrometry, wherein a liquid chromatography condition mobile phase comprises ultrapure water (a mobile phase A) containing 0.1% of formic acid and acetonitrile (a mobile phase B); the temperature of the chromatographic column is kept at 45 DEG C, and the sample size is 2L; the flow velocity of the mobile phase is set to be 0.3 mL / min, and the total operation time is 4.5 minutes; in mass spectrum conditions, a positive electrospray ionization mode is adopted, multiple reaction monitoring (MRM) is adopted, and multi-reaction monitoring is adopted as a scanning mode. The method is high in sensitivity, the lowest quantitative concentration can reach 50 ng / mL, and accurate, rapid and sensitive determination of the elacycline in the human serum can be realized.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

The present invention relates to a pamoate drug sustained-release microsphere and a preparation method therefor. A sustained-release microsphere formulation for injection prepared according to the preparation method of the present invention has a relatively narrow microsphere particle size distribution, and the release time of active pharmaceutical ingredients of a drug can last for about three to four months. In addition, the microsphere formulation prepared by the present invention can maintain stable plasma concentration in an animal body, and has no relatively large plasma concentration fluctuation within three to four months, thereby better avoiding the occurrence of toxic and side effects.

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.

A lithographic apparatus (100) includes: a housing (400) defining an environment (401), where the environment surrounds a surface (402), where the housing is configured to contain a plasma; a microwave generator (410) configured to provide microwave radiation (411) into the housing; and a magnetic source (420) configured to generate a magnetic field adjacent to the surface, the magnetic field generating a plasma (432) by electron cyclotron resonance together with the microwave radiation, thereby increasing the concentration of the plasma adjacent to the surface.

The invention provides application of a biomarker cyclic dinucleotide cGAMP in diagnosis and risk prediction of myocardial infarction. The application specifically relates to application of the biomarker cyclic dinucleotide cGAMP in preparation of a myocardial infarction diagnosis tool, application of the biomarker cyclic dinucleotide cGAMP in preparation of a myocardial infarction risk prediction product and application of the biomarker cyclic dinucleotide cGAMP in construction of a myocardial infarction risk prediction model. Experimental results show that the concentration of cGAMP in plasma of a patient suffering from coronary heart disease and the risk of suffering from myocardial infarction are in a remarkable U-shaped relationship, the risk of myocardial infarction can be increased compared with the cGAMP with too high or too low critical concentration, and the critical concentration is 1352 ng / L. Whether the plasma concentration is greater than or less than the critical concentration, the cGAMP has medium diagnostic ability to myocardial infarction.

A technique is provided for identifying correct or sufficient doses in a patient being treated with a drug for a neurological deviation condition. A method may include performing a plurality of fright response tests on a user, each test utilizing a device having a camera, a display, and optionally a speaker, and each test occurring at a different time after the user has been administered a medicament. The method may include receiving a plurality of images of at least one eye of the user from a camera during each test, and then calculating a magnitude of eyelid closure based on each image. The method may include determining a value of a correlation between a predetermined plasma concentration of the drug and the determined amplitude, and then determining whether a correct or sufficient dose has been reached based on the value of the correlation.

The present invention relates to the crystalline form of bipyrimidine compounds, as well as methods for preparing the same and their use. In particular, the present invention relates to crystalline form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)bicyclo[2.2.2]octan-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, wherein the X-ray powder diffraction pattern of crystalline form I includes characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2° and 22.200±0.2°. Crystal form I possesses high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological activity, making it suitable for pharmaceutical preparations.

The present disclosure relates to a method of providing sustained energy from a beverage comprising one or more stimulants, such as caffeine, comprising (a) administering the beverage comprising one or more stimulants to a consumer; (b) measuring the consumer's plasma concentration of the one or more stimulants over a first time period; (c) measuring the consumer's visual analog scale (VAS) response over a second time period; and (d) increasing or decreasing the amount of the one or more stimulants in the beverage based on the measurements from (b) and (c). The method can further comprise measuring a baseline for each of the consumer's plasma concentration and VAS response prior to (a). The method can also further comprise measuring one or more vital signs, such as heart rate or blood pressure, of the consumer prior to (d) in a third time period.

Provided are intermittent administration methods for reducing toxicity in the treatment of conditions associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression levels in a subject with a 15-PGDH inhibitor. Further, provided herein are methods of treating a condition associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression level in a subject by administering a 15-PGDH inhibitor while maintaining the therapeutic effect of the 15-PGDH inhibitor when the plasma concentration of the 15-PGDH inhibitor in the subject drops below the EC50 of the 15-PGDH inhibitor.

The present invention relates to a syrup containing alectinib or a salt thereof. The present invention provides a syrup containing alectinib or a salt thereof, which is a poorly water soluble agent, and having improved fluidity and / or palatability. The syrup of the present invention has a plasma concentration profile equivalent to or greater than, or is biologically equivalent to, a capsule containing the same amount of alectinib or a salt thereof as the syrup, or has an enhanced oral bioavailability compared to a capsule containing the same amount of alectinib or a salt thereof as the syrup.

The application relates to the technical field of pharmaceutical analysis, and discloses a pharmacokinetic analysis method of Tongwei Xiaozheng medicinal liquid, which adopts Q-Orbitrap high-resolution liquid chromatography-mass spectrometry to analyze the concentration of Jasmonic acid in blood components of the Tongwei Xiaozheng medicinal liquid in rat plasma, establishes a plasma concentration determination method for the blood original component Jasmonic acid, carries out methodological verification such as specificity, precision and accuracy, and then calculates pharmacokinetic parameters. In the Tongwei Xiaozheng medicinal liquid, 92 blood components are identified, 17 of which are original components and 75 of which are metabolites, the application firstly determines that Jasmonic acid is one of the blood original components of the Tongwei Xiaozheng medicinal liquid, and reveals the pharmacokinetic characteristics of the Jasmonic acid in normal and model rats. The method has strong specificity, high sensitivity and good reproducibility, and can provide a scientific basis for the research on the pharmacodynamic material basis of the Tongwei Xiaozheng medicinal liquid, the establishment of quality control standards and the clinical rational use of drugs.

The present invention relates to an oral extended-release dosage form of 7-methylxanthine (7-MX) or a pharmaceutically acceptable salt thereof. The dosage form is designed for twice-daily administration and provides controlled release of the active agent, achieving pharmacokinetic characteristics including sustained plasma concentrations and reduced fluctuation compared to immediate-release formulations. The invention further relates to the use of such dosage forms in the treatment of myopia, wherein the extended-release characteristics enhance therapeutic effectiveness in myopia.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.

The invention discloses a plasma field uniformity adjusting device which comprises a cavity cover, a coil, a first adjusting piece, an air nozzle and a second adjusting piece, and through the first adjusting piece and the second adjusting piece, when a small-size wafer is processed or the plasma concentration of a central area needs to be increased, the coil can rotate and contract centripetally so as to increase the central field intensity; the gas nozzle can be close to the center of the working cavity to increase central gas concentration; when a large-size wafer is processed or the plasma concentration of a central area needs to be reduced, the coil can be centrifugally rotated and diffused to reduce the central field intensity, and the gas nozzle can be far away from the center of the working cavity to reduce the central gas concentration; the distribution of plasmas can be improved in a targeted manner by winding and unwinding the coil or changing the radial position of the air tap; and through cooperative adjustment of the coil and the gas nozzle, dynamic matching of plasma distribution and reaction gas conveying can be realized, and improvement of process uniformity and equipment adaptability is facilitated.

The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

A bremelanotide pharmaceutical composition, a formulation thereof, a preparation method therefor, and use thereof. The bremelanotide pharmaceutical composition comprises bremelanotide as a pharmaceutically active ingredient, a solvent, and a polymer. The solvent includes one or more of N-methylpyrrolidone, polyethylene glycol, dimethyl sulfoxide, and benzyl benzoate and enables the plasma concentration of bremelanotide to be stably greater than 0.1 ng / mL at 120-168 h, thereby achieving the target sustained release. The bremelanotide pharmaceutical composition can be directly injected and does not require the addition of a thickener, a gel-forming agent, or other excipients.

The application provides a plasma spray gun device compatible with near-normal-pressure photoelectron spectroscopy, and relates to the field of in-situ spectroscopy characterization.The first aspect of the application provides a plasma spray gun device compatible with near-normal-pressure photoelectron spectroscopy, which can realize the synchronization of gas delivery and plasma generation at the same position, guarantee the uniformity of the plasma entering the chamber for in-situ characterization experiments, and can concentrate the plasma in the test area, so that the plasma concentration on the surface of the sample is increased, and the surface reaction of the sample is improved.The second aspect of the application provides an in-situ photoelectron spectroscopy characterization device.

A pharmaceutical composition containing minoxidil, which is composed of minoxidil, a filler, a sustained-release material, a glidant and a lubricant, wherein the specification of minoxidil is 1.25-5.0 mg, and the sustained-release material is selected from hypromellose. The minoxidil composition has a sustained-release effect of 8-12 hours in vitro, has an ideal in-vivo plasma concentration and bioavailability, and ensures the safety and effectiveness of the use of minoxidil.

Disclosed is use of a combined compound medicine in treating pathogenic bacteria persistent infection. Existing antibiotic monotherapy or combination therapy is usually difficult to kill pathogenic bacteria in the persister state, especially nutrient-insensitive persister bacteria, which often lead to a series of problems of long treatment period, frequent condition recurrence and deterioration, treatment failure, drug-resistant mutation, etc. At present, drugs capable of efficiently killing highly persistent pathogenic bacteria in a clinically applicable concentration range are still unavailable. The novel compound medicine of polymyxin and aminoglycoside antibiotics disclosed in the present disclosure without precedence is capable of destroying bacterial cell membranes in a short time within a relatively wide range of clinically achievable plasma concentrations, leading to rapid death of a large number of bacteria, but is safe for human-derived cells. Therefore, the compound medicine is expected to be applied to the clinical treatment of various acute or chronic infectious diseases caused by pathogenic bacteria in the persister state, shortening the treatment course, preventing the recurrence of infection recurrence, and slowing down the emergence of drug-resistant mutations.

The invention relates to the technical field of cells, and particularly discloses an amino acid culture medium for promoting synthesis of casein of dairy cow mammary cells and a preparation method. In the culture medium, the addition amount of lysine is 0.74 mmol / L, the addition amount of threonine is 0.22 mmol / L, and the addition amount of phenylalanine is 0.28 mmol / L. Tests prove that the culture medium under the condition of the application can obviously improve the relative proliferation rate and casein expression quantity of dairy cow mammary gland cells compared with a culture medium under 4 times of plasma concentration (optimal amino acid supply mode) of dairy cow. The method for promoting casein synthesis comprises the following steps: culturing cow mammary epithelial cells to P3 generation; when the P3 generation cells grow to 75-85% of the adherent area in a 75 cm < 3 > culture flask, transferring the P3 generation cells into a culture medium without lysine, threonine and phenylalanine, and starving for 16 hours; when the cells are hungry, transferring the cells into the culture medium prepared by the invention to be continuously cultured for 24 hours; and after culture is finished, measuring the relative proliferation rate and casein expression quantity of the cells.

The invention discloses an application of a synephrine dry powder inhalant in preparation of a medicine for treating acute lung injury. According to the invention, the synephrine is prepared into a dry powder inhaler (DPI) dosage form, so that the problem of low bioavailability of the synephrine is overcome, and the synephrine is directly and actively targeted to the lung after being administered to the lung, so that the plasma concentration of the lung is increased, and the distribution of the medicine in other tissues is reduced, thereby improving the curative effect of the medicine and reducing the side effects of the whole body. Meanwhile, the first-pass effect is avoided by a dry powder inhalation mode, so that the stability of the medicine is facilitated, and the treatment compliance of a patient is improved by a non-invasive administration way. The invention provides a new thought for the research of a pulmonary drug delivery system, and has a wide clinical application prospect.

The invention relates to the technical field of biological medicine, in particular to centipeda minima extracellular vesicle nose drops and a preparation method and application thereof.The centipeda minima extracellular vesicle nose drops comprise active ingredients, plant extracellular vesicles (Cm-EVs) derived from centipeda minima, the concentration of the plant extracellular vesicles (Cm-EVs) is 1 * 10 < 10 >-5 * 10 < 11 > particles / ml; the key active substances are as follows: the content of the Cm-EVs naturally encapsulated sesquiterpene lactone compound centipederin is more than or equal to 50 micrograms per milliliter (detected by HPLC-MS); the pharmaceutical auxiliary materials comprise 0.05 to 0.2 percent (w / v) of sodium hyaluronate, 0.8 to 1.0 percent (w / v) of NaCl and 0.005 to 0.02 percent (v / v) of polysorbate 80; the method has the beneficial effects that the targeted enrichment capability is realized: mucous membrane adhesion is enhanced through surface pectin protein, and the nasal cavity residence time is prolonged to 6 hours (the free medicine is less than 1 hour); the nano-scale particle size (80-200nm) can efficiently penetrate through the mucous layer, and the nasal mucosa drug concentration reaches 20 times of the plasma concentration (rat pharmacokinetic data); the long-acting slow-release property is as follows: the active ingredients are protected by the lipid bilayer, the cumulative release rate of the centipederin within 72 hours reaches 82%, and the free medicine can be completely released within 24 hours.

The invention discloses a method for detecting the plasma concentration of polymyxin E. L-PME1 is used as an internal standard, a liquid chromatography-tandem mass spectrometry detection method is adopted for detection, the extraction efficiency and the mass spectrometry ionization efficiency are far superior to those of a common structural analogue internal standard, and a high internal standard synchronization rate can be kept in different matrixes. In addition, the L-PME1 does not exist in a natural polymyxa fermentation product, so that cross influence cannot be generated.

This application relates to the field of flush probe evaluation, and specifically discloses a method for evaluating the accuracy of flush probe in high-temperature dynamic plasma diagnosis. Through theoretical calculations and test results of a high-enthalpy wind tunnel, the accuracy of directly using flush probes for measuring the plasma concentration in a high-temperature dynamic flow field is quantitatively evaluated, and a comparative evaluation of the detection data between electrostatic probes and flush probes is achieved.